Invivyd selects VYD-222 to advance as monoclonal antibody therapeutic option for COVID-19

March 7, 2023

Invivyd Inc. has selected VYD-222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19. VYD-222...